Compare AbbVie Inc (ABBV) vs Atmos Energy Corporation (ATO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Atmos Energy Corporation — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while Atmos Energy Corporation trades at $177.38 (market cap $29.64B). The key difference: AbbVie Inc is far larger — about 15.2× Atmos Energy Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | ATO | |
|---|---|---|
Market Cap | $449.91B | $29.64B |
Sector | Health | Utilities |
52-Week High | $261.07 | $192.25 |
52-Week Low | $184.85 | $151.99 |
Enterprise Value | $513.38B | $39.15B |
Dividend Yield | 2.72% | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
ATO trades at $177.58, up 0.4% today, with a bearish technical signal but neutral oscillators. Recent earnings beat expectations in Q1 2026, with revenue growth to $4.7B in 2025 and a net margin of 27.58%. The stock shows strong profitability and a P/E of 21.41, while analyst consensus is a Buy with a $188.86 target. A dividend of $1.00 was recently declared, supporting income appeal.
Outlook is positive due to earnings beats and defensive utility positioning, but risks include high capital expenditures and debt levels. Investment opportunity lies in steady growth and dividend consistency, though market volatility and interest rate sensitivity pose challenges for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →
